neurotez

Robert Winkler, MD joined a stealth Biotech as Chief Medical Officer in late 2018 bringing extensive experience in Global Clinical Development with multiple regulatory approvals as well as Medical Affairs…

Dr. Robakis is A.P. Slaner Professor for Neurobiology of Alzheimer’s Disease Research and Director of the Center for Molecular Biology and Genetics of Neurodegeneration at Mount Sinai School of Medicine…

Most recently CEO and on the Board of Directors of Jade Therapeutics (acquired by EyeGate Pharmaceuticals in 2016) and Gem Pharmaceuticals (acquired by Monopar Therapeutics in 2017), Klausner was Chief…

Lex is CSO at Rhythm Pharmaceuticals. He is also Manager for VDP, LLC, an independent consulting agency focused on guiding Research and Development for the Biotechnology and Pharmaceutical Industries and…

Dr. Lawrence Friedhoff was responsible for the development and launch of Aricept® the market leading Alzheimer’s disease drug. Dr. Friedhoff is the President and Founder of the Pharmaceutical Special Projects…

Gilbert A. Block, MD, PhD, has more than 23 years of pharmaceutical and biotechnology experience encompassing all aspects of clinical development and translational medicine; focusing primarily on neurosciences. Dr Block…

Daniel P. Van Kammen, MD, PhD has held successful leadership positions in CNS Clinical Development of large Pharma, such as Johnson & Johnson and Aventis/Sanofi (where he was head of…

Julio Licinio, M.D., FRANZCP, is Deputy Director for Translational Medicine and Head, Mind and Brain Theme at the South Australian Health and Medical Research Institute and Strategic Professor of Psychiatry,…

David Mapley is Chairman, Shimoda Capital Partners and Shimoda Group. He has spent 35 years working in the Financial Markets in New York, Hong Kong, London, Sydney, Tokyo, Toronto and…